258 related articles for article (PubMed ID: 20178475)
1. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
Blondeau JM
Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
[TBL] [Abstract][Full Text] [Related]
2. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
3. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
Zhao X; Drlica K
J Infect Dis; 2002 Feb; 185(4):561-5. PubMed ID: 11865411
[TBL] [Abstract][Full Text] [Related]
4. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Allen GP; Bierman BC
Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
[TBL] [Abstract][Full Text] [Related]
6. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA).
Allen GP; Deshpande LM
Int J Antimicrob Agents; 2010 Jan; 35(1):45-9. PubMed ID: 19910164
[TBL] [Abstract][Full Text] [Related]
7. Mutant selection window hypothesis updated.
Drlica K; Zhao X
Clin Infect Dis; 2007 Mar; 44(5):681-8. PubMed ID: 17278059
[TBL] [Abstract][Full Text] [Related]
8. The mutant selection window and antimicrobial resistance.
Drlica K
J Antimicrob Chemother; 2003 Jul; 52(1):11-7. PubMed ID: 12805267
[TBL] [Abstract][Full Text] [Related]
9. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
10. Emergence and spread of antibiotic resistance following exposure to antibiotics.
Cantón R; Morosini MI
FEMS Microbiol Rev; 2011 Sep; 35(5):977-91. PubMed ID: 21722146
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Allen GP; Hankins CD
J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
[TBL] [Abstract][Full Text] [Related]
12. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
13. The mutant selection window in rabbits infected with Staphylococcus aureus.
Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus.
Quinn B; Hussain S; Malik M; Drlica K; Zhao X
J Antimicrob Chemother; 2007 Dec; 60(6):1380-3. PubMed ID: 17905797
[TBL] [Abstract][Full Text] [Related]
15. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
[TBL] [Abstract][Full Text] [Related]
16. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
17. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus.
Lu T; Zhao X; Li X; Hansen G; Blondeau J; Drlica K
J Antimicrob Chemother; 2003 Jul; 52(1):61-4. PubMed ID: 12805268
[TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial susceptibility testing of bacteria isolated from animals: considerations concerning the predefinition of breakpoints from the clinical pharmacological viewpoint].
Kietzmann M; Böttner A; Hafez HM; Kehrenberg C; Klarmann D; Krabisch P; Kühn T; Luhofer G; Richter A; Schwarz S; Traeder W; Waldmann KH; Wallmann J; Werckenthin C; ;
Berl Munch Tierarztl Wochenschr; 2004; 117(3-4):81-7. PubMed ID: 15046455
[TBL] [Abstract][Full Text] [Related]
19. [Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria].
Liang QF; Wang ZQ; Li R; Luo SY; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2009 Jan; 45(1):61-5. PubMed ID: 19484933
[TBL] [Abstract][Full Text] [Related]
20. The changing face of antibiotic prescribing: the mutant selection window.
Epstein BJ; Gums JG; Drlica K
Ann Pharmacother; 2004 Oct; 38(10):1675-82. PubMed ID: 15340128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
